Published September 27, 2026
The global settlement Pfizer signed in July to resolve federal Depo-Provera meningioma lawsuits is moving from agreement to administration. In early September, U.S. District Judge M. Casey Rodgers, who oversees the multidistrict litigation (MDL 3140) in the Northern District of Florida, put the people in place who will manage the money, and the court has set November 30, 2026 as the date by which plaintiffs must register to take part.
On September 9, Judge Rodgers issued two orders. The first appointed Matt Garretson of Garretson, LLC as Allocation Master for the settlement's Supplemental Compensation Fund, the role responsible for how that pool of money is divided among eligible claimants. The second named CPA Randall Sansom to administer the Qualified Settlement Fund, the account that holds settlement money before it is paid out. BrownGreer is serving as the settlement administrator handling registration.
Reporting on the court's September 14 docket counted 6,411 federal cases representing 6,775 plaintiffs. Of those, 5,755 plaintiff questionnaires had been submitted and 4,696 had been judged complete, and 6,386 plaintiffs had met the separate registration requirement set out in Pretrial Order 23.
The key date is November 30, 2026. After that deadline passes, BrownGreer is expected to identify which plaintiffs remain in active litigation rather than in the settlement, and those plaintiffs will face stricter proof requirements to keep their cases moving. Back in July, the parties told the court they expected registration to wrap up in November, with claims processing and the first payments beginning in the first quarter of 2027. The individual payout amounts and eligibility criteria remain confidential, and Pfizer has not admitted wrongdoing.
The settlement does not end the MDL for everyone. The court scheduled a September 18 hearing on Pfizer's general causation and Rule 702 challenges, which test whether plaintiffs' experts can reliably link the injection to meningioma. Those rulings are not expected to affect plaintiffs who join the settlement, but they will matter for anyone who is ineligible or chooses to keep litigating. As of this writing, no ruling from that hearing had been reported. The court has also chosen three replacement pilot cases to test Pfizer's statute-of-limitations defenses on a faster schedule. Cases filed in state courts run on a separate track and are not covered by the federal agreement.
If you used Depo-Provera and were later diagnosed with a meningioma, timing matters. The federal registration window has a firm end date, and state filing deadlines run independently of the settlement. See Atumio's Depo-Provera case page for a free, no-obligation review, or start your case review directly.